Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
复制标题
DOI：
10.1093/annonc/mdq706
复制
发表时间：
2011-09-01
影响因子：
50.5
通讯作者：
Lipton, A.
中科院分区：
文献类型：
--
作者：
Bates, M.;Sperinde, J.;Lipton, A.
背景资料：与转移性乳腺癌（MBC）过度表达HER2（人表皮生长因子受体2）的患者目前选择与曲妥珠单抗治疗，但不是所有的患者respons.Patients和方法：使用一种新的分析，HER2蛋白表达（H2T）测定福尔马林固定，石蜡包埋的原发性乳腺肿瘤从98名妇女治疗与曲妥珠单抗为基础的治疗MBC。利用亚群体处理效应模式图，将群体分为H2T低（H2T < 13.8）、H2T高（H2T >= 68.5）和H2T中等（13.8
Background: Patients with metastatic breast cancer (MBC) overexpressing HER2 (human epidermal growth factor receptor 2) are currently selected for treatment with trastuzumab, but not all patients respond.Patients and methods: Using a novel assay, HER2 protein expression (H2T) was measured in formalin-fixed, paraffin-embedded primary breast tumors from 98 women treated with trastuzumab-based therapy for MBC. Using subpopulation treatment effect pattern plots, the population was divided into H2T low (H2T < 13.8), H2T high (H2T >= 68.5), and H2T intermediate (13.8